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Abstract 
Objectives: To assess if psychiatrists were influenced by a patient’s genetic information, 
even when the patient’s response to treatment was already known to them. 
 
Methods: Sixty-seven psychiatrists were presented with patients' pre and post-treatment 
scores on the PANSS for two hypothetical treatments for schizophrenia. Psychiatrists were 
also informed whether the patient possessed a genotype linked to hyper-responsiveness to one 
of the treatments, and were asked to recommend one of these two treatments. Attribute non-
attendance assessed whether the information on genotype influenced psychiatrists' treatment 
recommendations. 
Results: Years of experience predicted whether psychiatrists were influenced by the genetic 
information. Psychiatrists with one year or less of experience had a 46% probability of 
considering genetic information, while psychiatrists with at least 15 years of experience had a 
lower probability (7%).   
Conclusions: Psychiatrists and other clinicians should be cautious about allowing a patient's 
genetic information to carry unnecessary weight in their clinical decision making. 
 
 
 
 
 
 
 
 
 
 
Introduction 
Clinicians are becoming increasingly aware of how a patient’s genotype can influence their response 
to treatment [1]. Tailoring treatments according to this anticipated response is known as stratified, or 
personalized, medicine [2]. In psychiatry, some genetic profiles in the population are associated with 
an increased risk of schizophrenia. Furthermore, some genetic profiles signal higher potential benefits 
of particular antipsychotic treatments [3,4], suggesting that for some patients psychiatric treatments 
could, in the future, be tailored to their genetic profile. However, whether or how information about a 
patient’s genetic profile influences psychiatrists’ treatment recommendations is still unclear.  
Genetic information may indicate the potential benefits that a patient could receive from a treatment 
but is redundant when the patient’s actual response to a treatment is known. Thus, in certain 
circumstances, genetic information about a patient could bias the psychiatrist’s clinical decision 
making. In particular, clinicians may view treatment outcomes differently when they are aware that 
the patient possesses a genotype that is indicative of hyper-responsiveness to a treatment. 
Consequently, if aware of a patient’s genetic profile, a clinician may be less or more likely to 
recommend or continue a treatment even though the treatment may have been shown to be effective in 
the patient’s pre- or post-treatment scores on a given symptom report scale. The potential for genetic 
information to bias clinical decision making in respect of  a patient’s treatment is known as 
pharmacogenetic exceptionalism [5]; this may result in an inefficient allocation of resources for 
public health. This paper explores the topic by using a choice-format conjoint analysis (referred to as 
a discrete-choice experiment [DCE]) administered to psychiatrists in Northern Ireland, United 
Kingdom (UK). 
In the practice of DCEs, respondents are presented with a sequence of choices for alternative options 
and are asked to select the one they prefer, with each alternative being described by different 
attributes and attribute levels [6–9]. A recent review showed a substantial increase in the application 
of DCEs in health economics and medical decision making and a desire to incorporate patients’ and 
doctors’ preferences in the study of effectiveness of treatments[10]. Indeed, the Food and Drug 
 
 
Administration recently stated that new cancer treatments must first assess patient preferences before 
becoming widely available to all patients [11] The conventional underlying assumption of DCEs is 
that, when choosing between alternatives, respondents rationally consider all the attributes presented 
and select the alternative that maximizes their utility. However, research has seen an increasing focus 
on decision-making heuristics [12–14]. One particular type of heuristic widely explored by choice 
modelers in transportation [15–17] and environmental economics [18–20] is attribute nonattendance 
(ANA). In ANA, respondents may ignore one or more attributes that they believe are not relevant in 
order to simplify the process of choosing the best alternative [21]. The importance of ANA in 
modelling respondents’ choices and preferences has been highlighted by its influence on both 
coefficient estimations and welfare analysis [17,22]. Recently, ANA also has been extended to health 
economics [14,23] where researchers warn that not accounting for ANA may lead to biased health 
policies [24]. However, within the context of medical decision-making research, ANA has not been 
widely used to assess which attributes (if any) are non-attended [23]. Researchers consider ANA a 
non- rational heuristic that should be included in the analysis to avoid bias but should not be included 
if respondents acted rationally, as assumed by the framework in which DCE operates. This study 
departs somewhat from this perspective, as ANA is considered the correct heuristic that a clinician 
should apply as the patient’s response to treatment is already known, making the patient’s genotype 
information redundant.  
This article’s contribution to the literature is twofold. From the methodological viewpoint, ANA is 
applied in a new, current and highly relevant context—stratified medicine—tackling the issues of 
coherence of information assessment in the psychiatrist’s treatment selection. The novel 
methodological aspect here is the use of ANA to improve the understanding of the extent to which 
medical decision making incorporates irrelevant information. From a clinical perspective, the article 
aims to contribute to the topical issue of whether genotype information influences the treatment 
recommendations of psychiatrists when a patient’s treatment response (in terms of symptom 
improvement) is already known to the psychiatrist.  
 
 
 
Analytic framework 
Analysis of DCE is based on the random utility maximization theory [25,26] where the underlying 
assumption is that individuals select the alternative that offers them the highest utility. In this context, 
it is possible to denote with i the treatment that psychiatrist n recommended when considering the 
vignette t. The utility function that psychiatrists maximize when recommending a treatment can be 
described by characterizing each vignette using a vector of attributes (X) and a vector of parameters to 
be estimated () as follows: 
𝑈𝑛𝑖𝑡 = 𝛽
′𝑋𝑛𝑖𝑡 + 𝜀𝑛𝑖𝑡 ,                                       (1) 
where ε represents the part of the utility function that the researcher cannot observe and is assumed to 
be an independent and identically Gumbel–distributed (i.i.d.) error term. With these definitions and 
assumptions, it is possible to mathematically specify the choice probability for each psychiatrist n 
selecting treatments i over j alternatives in the vignette t, as a multinomial logit (MNL) selection 
probability [26]: 
Pr(𝑛𝑖𝑡) =  
exp(𝛽′𝑋𝑛𝑖𝑡)
∑ exp(𝛽′ 𝑋𝑛𝑗𝑡)
𝐽
𝑗=1
.   (2)  
This model is estimated as a benchmark and is the simplest starting point for behavioral analysis. 
Notwithstanding the importance and practicality of the MNL model results, the MNL has several 
restrictive assumptions. For example, preferences are homogenous across respondents and choices are 
independent from irrelevant alternatives. These assumptions are often considered unrealistic and are 
likely to bias the results [28]. The mixed logit (MXL) model relaxes the restrictive assumptions 
underlying the MNL model and accommodates for the possibility that respondents may have different 
preferences [29]. Furthermore, the model fit to observed data is typically improved when estimating 
MXL models [30]. The models derived under the general framework of the MXL allow for taste 
parameters to vary across respondents and to account for the fact that, in the DCE, each respondent 
is observed across a series of T vignettes and therefore can be represented as a balanced longitudinal 
panel of responses on experimentally designed choice tasks (vignettes). If the value of were known 
for each of the n
th 
respondents, the probability of a sequence of choices would be given by: 
 
 
       Pr(𝑦𝑇𝑛|𝛽, 𝑋𝑛𝑖𝑡) = ∏
exp (𝛽′𝑋𝑛𝑖𝑡)
∑ exp (𝛽′𝑋𝑛𝑗𝑡)
𝐽
𝑗=1
𝑇
𝑡=1 .  (3) 
Because it is impossible to know the value of  with certainty for each respondent, heterogeneity of 
preferences is estimated by allowing for random variation in  across respondents [31,32]. To address 
the research question, it is essential to understand whether psychiatrists are influenced by information 
about a patient’s genotype in making their treatment recommendations. Therefore, we were interested 
in modelling ANA in this context, while addressing preference heterogeneity. In this paper, ANA was 
analyzed by means of behavioral latent class (LC) models, which are semiparametric variants of the 
MNL model. In LC models, it is assumed that each individual respondent can be implicitly sorted into 
a set of C behaviorally defined classes associated with certain estimated probabilities, with each class 
characterized by a unique class-specific pattern of ANA embedded in the utility parameters, 𝛽𝑐. With 
membership to class c, the probability of respondent n’s sequences of choices 𝑦𝑇𝑛 over T choice 
occasions is:  
          Pr(𝑦𝑇𝑛|𝛽𝑐, 𝑥𝑛𝑖𝑡) = ∏
exp (𝛽𝑐
′ 𝑋𝑛𝑖𝑡)
∑ exp (𝛽𝑐
′ 𝑋𝑛𝑗𝑡)
𝐽
𝑗=1
𝑇𝑛
𝑡=1 .  (4) 
Considering that the membership probabilities π for each behavioral LC c are also defined according 
to a MNL process, we have: 
π𝑐 =  
exp (𝛼𝑐+𝛾𝑐
′𝑧𝑛)
∑ exp (𝛼𝑐+𝛾𝑐
′𝑧𝑛)
𝐶
𝑐=1
  ,  (5) 
where zn is a vector of covariates characterizing respondent n, and 𝛾𝑐 is the vector of associated 
parameters subject to estimation, while c is a class-specific constant. In the estimation of LC models, 
for identification purposes, only C-1 set of coefficients can be independently identified (e.g., for one 
arbitrary class c, the vector < c : 𝛾𝑐 = 0 >).  
The probability of a sequence of choices is: 
Pr(𝑦𝑇𝑛|𝑋𝑛𝑖𝑡) = (∑ 𝜋𝑐 ∏
exp(𝛽′𝑥𝑛𝑖𝑡)
∑ exp(𝛽′𝑥𝑛𝑗𝑡)
𝐽
𝑗=1
𝑇
𝑡=1
𝐶
𝑐=1 ).         (6) 
 
 
The primary hypothesis of this paper was that genotype information might influence some doctors 
even though this information is redundant. Therefore, this study first focused on a relatively reduced 
model specification where ANA affects only one attribute (genotype information). This resulted in a 
model with only two classes (we ignored ANA on attributes other than genotype information). Given 
the importance of heterogeneity, the final model accommodated for random variation of preferences 
across respondents by incorporating a random-parameters logit (RPL) model within each class. The 
final model estimated was represented as: 
Pr(𝑦𝑇𝑛|𝑋𝑛𝑖𝑡) =  ∫ (𝜋 ∏
exp (ANA𝛽′𝑥𝑛𝑖𝑡)
∑ exp (ANA𝛽′𝑥𝑛𝑗𝑡)
𝐽
𝑗=1
𝑇
𝑡=1 + (1 − 𝜋) ∏
exp (𝛽′𝑥𝑛𝑖𝑡)
∑ exp (𝛽′𝑥𝑛𝑗𝑡)
𝐽
𝑗=1
𝑇
𝑡=1 ) 𝑓(𝛽)𝑑𝛽,         (7) 
where (ANA𝛽′𝑥) denotes the indirect utility of the vignette for those doctors who ignored the 
information on genotype while those who attended to this information have an indirect utility of 𝛽′𝑥. 
The probability of nonattending to the information on genotype is represented by see equation 5 
Our second hypothesis was that doctors use other strategies to simplify the decision-making process 
(as doctors often have to make many decisions very quickly, they might use ANA to simplify their 
task). Therefore, we extended our behavioral investigation to explore the entire combination of ANA 
specifications. The combination of ANA behavior across the four attributes, each of which can be 
attended to or ignored, generated 2
4
=16 behavioral classes (Equation 6). The models were estimated 
using BIOGEME 2.2 [33].  
Methods 
Participants 
The sample comprised 67 practicing psychiatrists recruited in Northern Ireland. Respondents were 
tested during single-session continuous professional development meetings in three hospital trusts. 
Participants provided their demographic information, whether they had completed their specialist 
training, and, if so, years of experience in clinical practice and their subspecialty. More than half 
(59%) were male. Most (64%) had completed their specialist training. The average years of clinical 
experience in their specialty was 10 years (standard deviation, 7.19 years). Ethical permission was 
 
 
granted from the Queens University Belfast Ethics Committee. Each participant also provided 
informed consent before completing the study. 
Vignette design 
Twenty-six vignettes were developed to assess the effect of each attribute on psychiatrists’ treatment 
recommendations for patients with schizophrenia (Figure 1). Each vignette provided a hypothetical 
patient’s pre- and post-treatment symptom scores on the positive subscale of the Positive and 
Negative Syndrome Scale (PANSS) for two treatments. The positive subscale of the PANSS consists 
of seven symptom report items, each rated on a 7-point scale, ranging from “absent” (numerical 
value=1) to “extreme” (numerical value=7). The scores are summed across the seven items to 
generate a total positive subscale score, ranging from 7 to 49, with higher scores indicative of more 
extreme symptoms [34]. All vignettes presented a pretreatment score of 42, indicating severe positive 
symptoms of schizophrenia prior to treatment [34]. Across the vignettes, the pre- post-treatment 
change scores ranged from 3 to 26 points.  
[Figure 1 about here] 
Figure 1. Example vignette. Each treatment showed the full range of scores on the PANSS with arrows showing 
the patient’s pre- and post-treatment scores. Vignettes indicated for which treatment the patient had a hyper-
responsiveness genotype. Respondents were asked to state which treatment they would be willing to recommend 
based on the information available. 
 
Each vignette also identified whether the patient had a genetic biomarker for one of the treatments:  
participants were told that the genetic biomarker was associated with a 30% increase in the 
effectiveness of the corresponding treatment. The biomarker was present for only one of the two 
treatments in each vignette. The vignettes additionally identified two side effects associated with each 
treatment. One side effect referred to the number of acute treatment days spent in hospital, ranging 
from 17 to 45 days. A second side effect referred to the likelihood of a 10-kg weight gain over the 
following 6 months, ranging from 30% to 70%, a common side effect associated with antipsychotic 
treatment [35–37]. The attributes and levels were based on discussions with two practicing 
psychiatrists to ensure that the attributes and levels fell within a realistic range that might be 
 
 
experienced in clinical practice. On the basis of the information provided in the vignettes, 
psychiatrists were asked which treatment they would recommend. 
Results 
As we were interested in understanding psychiatrists’ preferences for different characteristics of 
treatments when making a recommendation, we started by modelling their choices adopting an MNL 
model and an RPL model to account for heterogeneity in preferences. In both models (Table 1), 
psychiatrists were significantly more likely to recommend treatments associated with higher 
posttreatment benefits.  As expected, psychiatrists were also significantly less likely to recommend 
treatments that were associated with more days spent in hospital or a higher likelihood of a 10-kg 
weight gain. Interestingly, psychiatrists were less likely to recommend treatments for which the 
patient had a hyper-responsiveness genotype.  
Table 1. Model estimations for MNL, RPL, and RPL nonattendance models. 
 MNL model  RPL model  RPL – ANA model 
Variable Estimate  SE  Estimate  SE  Estimate  SE 
            
Change score 0.30***   0.02   0.44***  0.04   0.44***  0.04 
σ Change score      0.19***  0. 03   0.20***  0.03 
            
Genotype -0.17**   0.09  -0.25  0.17  -2.02***  0.36 
σ Genotype      1.02***  017   0.16  0.91 
            
Days -0.08***   0.01  -0.11***  0.01  -0.11***  0.01 
σ Days      0.04***  0.02   0.04***  0.02 
            
Weight gain -0.08***   0.01  -0.11***  0.01  -0.10***  0.01 
σ Weight gain      0.04***  0.01   0.05***  0.01 
            
% of psychiatrists who 
considered patient’s 
genotype 
         
15.6% 
            
% of psychiatrists who 
did not considered 
patient’s genotype 
         
84.4% 
            
Variation in ANA 
Genotype info per year 
of experience 
        
0.17***  0.06 
            
Log-likelihood -594.69  -533.07  -532.63 
            
Parameters 4  8  9 
 
 
Note. MNL (multinomial logit), RPL (random parameters logit), RPL-ANA (Random parameters – attribute 
non-attendance), SE (standard error) 
**p<.05, ***p<.01 
 
 
Genotype and its influence on psychiatrists’ treatment recommendations 
To test the primary hypothesis related to psychiatrists’ attending to the irrelevant information about 
the patient’s genotype, a constrained LC model to control for ANA on only the genotype attribute (as 
described in equations 5 and 7) was estimated. This provided an estimated probability that 
psychiatrists systematically ignore the information about the patient’s genotype. The results of this 
analysis are reported in the last two columns of Table 1 (under the heading RPL-ANA model) and 
suggest that the genotype information did not significantly influence most of the psychiatrists’ 
treatment recommendations. Indeed, across the entire sample of psychiatrists, there was an 84% 
probability that psychiatrists’ did not consider the information on patient genotype. Nonetheless, there 
was a small probability (approximately 16%) that psychiatrists attended to the information on 
genotype. Although this probability is small, it implies that, in some instances, psychiatrists 
considered the genotype information to be important even though the patient’s treatment response on 
the PANSS was already known to them.  
To better characterize psychiatrists who were associated with a positive probability of considering a 
patient’s genotype information when selecting their preferred treatment, we tested the significance of 
various covariates likely to act as determinants of class membership probability (equation 6) and 
found years of clinical experience was the only significant covariate. Specifically, we found that more 
experienced psychiatrists were less likely to consider the information on genotype when selecting the 
treatment to recommend to the patients in the vignette. To be able to expand our discussion on the 
practical implication of this finding, we simulated posterior probabilities (based on the sequence of 
choices made by each physician) of being associated with one class or another conditionally to the 
numbers of years of experience. The result, as presented in Figure 2, suggests that psychiatrists with 
less than 1 year of experience had a probability close to 50% of attending to and incorporating the 
 
 
genotype information in their treatment recommendations. Conversely, psychiatrists with more than 
15 years of experience were not likely (with a membership probability close to zero) to consider the 
genotype information in their recommendations.
2
 
[Figure 2 about here] 
Figure 2. Psychiatrists’ years of experience plotted against the probability of attending to the patient’s 
genotype information. More experienced psychiatrists were less likely to attend to the genetic 
information of the patient. 
 
Discussion  
This study investigated whether psychiatrists’ treatment decisions are influenced by information about 
a patient’s genotype even when they already know the patient’s actual response to treatment. We 
provided psychiatrists with pre- and post-treatment patient outcomes, which identify a treatment’s 
effectiveness, and information about the patients’ genotype. Our premise was that the presence of a 
hyper-responsive genotype should not have influenced the treatments recommended by psychiatrists. 
Results suggested that most psychiatrists, but not all, were not influenced by the irrelevant genetic 
information about the patient. Years of clinical experience strongly determined whether psychiatrists 
incorporated the genetic information into their recommendations. Psychiatrists with 1 year or less of 
clinical experience had a 46% probability of responding to the genetic information. Psychiatrists with 
at least 15 years of experience had a 7% probability of incorporating the same genetic information. 
Why were inexperienced psychiatrists more likely to be influenced by irrelevant genetic information 
about a patient? One possibility is that the prescribing behaviors of psychiatrists have undergone a 
gradual change over time, creating generational differences in their recommendations [38]. Another 
                                                          
2
 To conclude the exploration of ANA in our dataset, it is possible to use the same model with additional classes. More 
precisely, the full model requires creation of 16 separate classes to account for all possible patterns of ANA. Estimates from 
this model (not included in the paper but available on request) suggest that only three classes have a membership probability 
significantly different from 0: full attendance (with a membership probability of 21.6%), nonattendance to genotype 
(60.5%), and nonattendance to both genotype and weight gain (with the lowest probability below 10% and statistically 
insignificant). However, the membership probability of the latter class is reduced to almost zero when the specification 
accounts for preference heterogeneity as in our model (RPL – ANA model) in Table 1. This makes the ANA specification 
proposed in Table 1 the most suitable to model the data from this study. 
 
 
possibility is that, unlike more experienced practitioners, novice practitioners have been exposed to 
new discoveries in genetics and the potential value of patient genotype information as part of their 
medical training. Modern medical training has incorporated recent advances in genetics that were not 
known during the training of more experienced practitioners [39]. Nevertheless, current medical 
training may not provide adequate guidance on when genetic information about a patient should be 
used and how it should be incorporated into clinical recommendations and prescriptions. For instance, 
in 2010, only 56% of a sample of 217 chief psychiatrists in psychiatric residency programs in the 
United States reported receiving training on genetics during their residency, and those who did 
received no more than 3 hours of training [40]. Thus, although novice psychiatrists may receive 
training on psychiatric genomics, directing their attention to its relevance in clinical practice, they 
may not receive sufficient training on the appropriate use of such patient information. We tentatively 
recommend that researchers and policymakers investigate more closely current education practices in 
terms of psychiatric genomics.  
Our findings resonate with recent discoveries that clinicians’ treatment recommendations can be 
influenced by subjective factors about a patient. For example, researchers have found that clinicians 
are less likely to recommend amniocentesis—an invasive prenatal test for genetic and chromosomal 
abnormalities—when pregnancies were conceived by assisted reproductive technologies than when 
they were conceived spontaneously, even though the method of conception is irrelevant to the 
possibility of genetic or chromosomal abnormalities [41]. Our current findings reveal that genetic 
information about a patient may also influence psychiatrists’ treatment recommendations even when a 
patient’s actual response to treatment is known, although this is less likely among experienced 
psychiatrists.  
Our study has some limitations. We focused on the treatment recommendations of practicing 
psychiatrists. Further research is essential to assess how clinicians in other medical domains may be 
inappropriately influenced by genetic information in their medical decision making. Additionally, we 
presented psychiatrists with hypothetical patient outcomes for hypothetical treatments rather than use 
actual patient outcomes for real treatments. We did so to control for potential redundancies between 
 
 
attributes and to allow a broad range of attribute levels. Studies have validated the use of vignettes to 
study individual preferences [43,44]. Nevertheless, the decisions in vignette-based studies usually do 
not have the same financial, psychosocial, or emotional consequences of treatment decisions made in 
clinical practice. 
Conclusions 
Building on encouraging results from past research on ANA in environmental economics [21,45,46] 
and health [47][14], our study confirms that ANA is a valuable tool for analyzing clinical decision 
making. To the authors’ knowledge, this study is the first to suggest that less experienced psychiatrists 
may be inappropriately influenced by a patient’s genetic information in their clinical decision making. 
Several authors have warned clinicians about being unduly influenced by a patient’s genetic 
information, and it is plausible that more experienced clinicians may be more immune to the influence 
of a patient’s genetic profile [5,48]. The findings of this study show that less experienced psychiatrists 
may be more susceptible to a form of pharmacogenetic exceptionalism, giving undue weight to a 
patient’s genotype when they already know the patient’s actual response to treatment. As a result, it is 
possible that less experienced psychiatrists will be less likely to recommend effective treatments or 
continue with ineffective treatment plans when they are aware of a patient’s genetic profile.  
We believe that the results of our current study may have important implications for medical practice. 
With the increased knowledge and awareness of the role that genes play in a patient’s potential 
response to treatment, it is essential that psychiatrists and other clinicians weigh this information 
appropriately in their clinical decision making. Understanding the role that genetics plays in treatment 
response could help clinicians maximize treatment response and minimize treatment side effects [42]. 
However, there is a risk that too much weight could be given to a patient’s genotype, known as 
pharmacogenetic exceptionalism [5]. Psychiatrists and other health care professionals should be 
aware of the potential influence of a patient’s genetic information on their clinical decision making, 
and this should be considered and highlighted during their education and further training. 
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